Pharma Journalist -

Daiichi Sankyo Company, Limited and Boston Pharmaceuticals, Inc. announced that they have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.…
Read More...

Kedrion Biopharma and Kamada Ltd., two leading human-derived protein therapeutics companies, announced that KEDRAB™ has received U.S. Food and Drug Administration (FDA) approval for…
Read More...

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and…
Read More...

Otsuka Pharmaceutical and Mylan have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab…
Read More...

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, announced publication of positive data from a Phase 2 clinical trial…
Read More...

Ethris GmbH announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell…
Read More...

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a…
Read More...

Medivir AB and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir's nucleotide polymerase inhibitor for hepatitis C,…
Read More...